MedPath

Effect of oral hypoglycemic agent for postprandial hyperglycemia administered two times daily on glycemic control in patients with type 2 diabetes with Mitiglinide / Voglibose combination tablets

Not Applicable
Conditions
Type 2 diabetes
Registration Number
JPRN-UMIN000026185
Lead Sponsor
St.Marianna University School of Medicine
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
50
Inclusion Criteria

Not provided

Exclusion Criteria

1) Patients with contraindications against the use of mitiglinide calcium hydrate tablets and mitiglinide calcium hydrate/voglibose combimation tablets based on their package inserts. 2) Patients who had taken sulfonylureas, GLP-1 receptor agonists,glinide,a-GI, SGLT-2 inhibitors, insulin within 8 weeks (56 days) before the start of the study 3) Excessive drinkers 4) Patients with severe diabetic microangiopathy 5) Patients with severe liver / kidney function decline 6) Patients with severe heart disease 7) Patients with severe hypertension combined 8) Patients with open surgery or previous bowel obstruction 9)Patients who were judged to be ineligible to be ineligible by the investigator or sub-investigator

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath